A phase I dose-finding, pharmacokinetics and genotyping study of olaparib and lurbinectedin in patients with advanced solid tumors

Código QR

A phase I dose-finding, pharmacokinetics and genotyping study of olaparib and lurbinectedin in patients with advanced solid tumors

Abstract The poly (ADP-Ribose) polymerase (PARP) inhibitor olaparib has shown antitumor activity in patients with ovarian or breast cancer with or without BRCA1/2 mutations. Lurbinectedin is an ecteinascidin that generates DNA double-strand breaks. We hypothesized that the combination of olaparib an...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Andres Poveda, Ana Oaknin, Ignacio Romero, Angel Guerrero-Zotano, Lorena Fariñas-Madrid, Victor Rodriguez-Freixinos, Pedro Mallol, Raquel Lopez-Reig, Jose Antonio Lopez-Guerrero
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/d1515ed3222c482292aa0ffa3a73aad2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Orphan Drugs in Development for the Treatment of Small-Cell Lung Cancer: Emerging Data on Lurbinectedin
por: Kauffmann-Guerrero D, et al.
Publicado: (2020)

Olaparib nanoparticles potentiated radiosensitization effects on lung cancer
por: Wu M, et al.
Publicado: (2018)

Intraperitoneal delivery of NanoOlaparib for disseminated late-stage cancer treatment
por: Baldwin P, et al.
Publicado: (2018)

Population pharmacokinetics and dose optimization of vancomycin in neonates
por: Soon Min Lee, et al.
Publicado: (2021)

Effects of concurrent and staggered dosing of semi-solid enteral nutrients on pharmacokinetic behavior of antiepileptic drugs after oral administration in rats.
por: Katsuhito Nagai, et al.
Publicado: (2021)

Effects of concurrent and staggered dosing of semi-solid enteral nutrients on pharmacokinetic behavior of antiepileptic drugs after oral administration in rats
por: Katsuhito Nagai, et al.
Publicado: (2021)

COMPARISON OF INDIVIDUAL PHARMACOKINETIC DOSING TOOLS IN PATIENTS WITH HEMOPHILIA A
por: Can Alp GENÇ, et al.
Publicado: (2021)

Olaparib Is a Mitochondrial Complex I Inhibitor That Kills Temozolomide-Resistant Human Glioblastoma Cells
por: Luca X. Zampieri, et al.
Publicado: (2021)

Enhanced Anti-Cancer Effect of Folate-Conjugated Olaparib Nanoparticles Combined with Radiotherapy in Cervical Carcinoma
por: Li D, et al.
Publicado: (2020)

Effects of danofloxacin dosing regimen on gastrointestinal pharmacokinetics and fecal microbiome in steers
por: J. L. Halleran, et al.
Publicado: (2021)

Improvements in the Oral Absorption and Anticancer Efficacy of an Oxaliplatin-Loaded Solid Formulation: Pharmacokinetic Properties in Rats and Nonhuman Primates and the Effects of Oral Metronomic Dosing on Colorectal Cancer
por: Pangeni R, et al.
Publicado: (2020)

AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity
por: Jacqueline H. L. Fok, et al.
Publicado: (2019)

A Single- and Multiple-Dose Study to Evaluate the Pharmacokinetics of Fixed-Dose Grazoprevir/Elbasvir in Healthy Chinese Participants
por: Li H, et al.
Publicado: (2020)

Characterization, pharmacokinetics, and hypoglycemic effect of berberine loaded solid lipid nanoparticles
por: Xue M, et al.
Publicado: (2013)

Evaluation of the single-dose pharmacokinetics and pharmacodynamics of apixaban in healthy Japanese and Caucasian subjects
por: Frost C, et al.
Publicado: (2018)

Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects
por: Cui Y, et al.
Publicado: (2013)

Olaparib modulates DNA repair efficiency, sensitizes cervical cancer cells to cisplatin and exhibits anti-metastatic property
por: Chandra Bhushan Prasad, et al.
Publicado: (2017)

Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Integration of Enrofloxacin Following Single Oral Administration of Different Doses in Brown Trout (<i>Salmo trutta</i>)
por: Kamil Uney, et al.
Publicado: (2021)

Assessment to the Antifungal Effects in vitro and the Ocular Pharmacokinetics of Solid-Lipid Nanoparticle in Rabbits
por: Liang Z, et al.
Publicado: (2021)

PHARMACOKINETIC STUDY OF RISPERIDONE: APPLICATION OF A HPLC METHOD WITH SOLID PHASE EXTRACTION
por: TORRES V,PABLO, et al.
Publicado: (2011)

Echocardiographic Findings and Genotypes in Autosomal Dominant Polycystic Kidney Disease
por: Ryohei Miyamoto, et al.
Publicado: (2021)

H-Ferritin-nanocaged olaparib: a promising choice for both BRCA-mutated and sporadic triple negative breast cancer
por: S. Mazzucchelli, et al.
Publicado: (2017)

Population Pharmacokinetic Analysis and Dosing Optimization of Prophylactic Fluconazole in Japanese Patients with Hematological Malignancy
por: Yasutaka Sakamoto, et al.
Publicado: (2021)

Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma.
por: Olivier Mir, et al.
Publicado: (2012)

Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects [Corrigendum]
por: Cui Y, et al.
Publicado: (2014)

Pharmacokinetically guided dosing of oral sorafenib in pediatric hepatocellular carcinoma: A simulation study
por: John C. Panetta, et al.
Publicado: (2021)

Dose Tailoring of Vancomycin Through Population Pharmacokinetic Modeling Among Surgical Patients in Pakistan
por: Muhammad Muaaz Munir, et al.
Publicado: (2021)

Preparation, in vitro release, and pharmacokinetics in rabbits of lyophilized injection of sorafenib solid lipid nanoparticles
por: Zhang H, et al.
Publicado: (2012)

A genetic screen using the PiggyBac transposon in haploid cells identifies Parp1 as a mediator of olaparib toxicity.
por: Stephen J Pettitt, et al.
Publicado: (2013)

Effect of Missed Doses on the Therapeutic Effect of Methotrexate for Rheumatoid Arthritis: A Pharmacokinetic Modeling Study
por: Morrison A, et al.
Publicado: (2021)

Pharmacokinetics of ponazuril after administration of a single oral dose to green turtles (Chelonia mydas)
por: Elliott R. Jacobson, et al.
Publicado: (2021)

Dose-dependent effects of Hedyotis diffusa extract on the pharmacokinetics of tamoxifen, 4-hydroxytamoxifen, and N-desmethyltamoxifen
por: Yung-Yi Cheng, et al.
Publicado: (2022)

High Frequency rTMS Dosing for Smoking Cessation: Preliminary Findings
por: Christine Sheffer, et al.
Publicado: (2021)

Favorable Response to Olaparib in a Patient with Cancer of Unknown Primary Carrying a Germline BRCA1 R71K Mutation
por: Jia X, et al.
Publicado: (2021)

Plasma-Based Genotyping in Advanced Solid Tumors: A Comprehensive Review
por: Maisam Makarem, et al.
Publicado: (2021)

A surprising finding during solid‐phase gastric emptying scintigraphy
por: Anne‐Sophie Hambye, et al.
Publicado: (2021)

Contribution of cytochrome P450 and ABCB1 genetic variability on methadone pharmacokinetics, dose requirements, and response.
por: Francina Fonseca, et al.
Publicado: (2011)

Physiologically based pharmacokinetic modeling of nanoceria systemic distribution in rats suggests dose- and route-dependent biokinetics
por: Carlander U, et al.
Publicado: (2018)

Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors
por: Wu H, et al.
Publicado: (2015)

BKM120 sensitizes BRCA-proficient triple negative breast cancer cells to olaparib through regulating FOXM1 and Exo1 expression
por: Yu Li, et al.
Publicado: (2021)